FLUPENTHIXOL DECANOATE IN CRACK COCAINE SMOKING

点击翻译按钮获取中文摘要

"Crack" cocaine abuse often produces severe cocaine dependence that is refractory to available pharmacological and outpatient psychotherapeutic treatments. In an open pilot trial, we evaluated the efficacy o a depot xanthene requiring infrequent IM administration, flupenthixol decanoate, for cocaine withdrawal. Ten poor prognosis, outpatient "crack" cocain smokers were administered flupenthixol decanoate in an open-label, open- ended trial. flupenthixol decanoate was well tolerated, and appeared to markedly and rapidly decrease cocaine craving and use, producing a 260% per cent increase over prior treatment in these subjects in their average time retained in treatment. This application proposes a double-blind flupenthixol decanoate trial with a comparison to a current oral pharmacotherapy, desipramine. Ninety "crack" cocain abusers will be treated in a clinical trial with randomized treatment comparing three contrasting pharmacological treatments added to conventional psychotherapy: (a) Placebo Desipramine plus Placebo I.M. Flupenthixol de==Decanoate (n=30) (b) Desipramine plus Placebo I. M. Flupenthixol Decanoate (n=30). Outcomes will be multidimensional. Twelve month follow- up evaluations will be performed to evaluate the durability and/or delayed emergence of treatment effects.